Predictors of Acute Encephalopathy in Patients with COVID-19

Oleg I Vinogradov, Tatyana K Ogarkova, Kamila V Shamtieva, Pavel V Alexandrov, Astanda V Mushba, Daria S Kanshina, Daria V Yakovleva, Maria A Surma, Ilia S Nikolaev, Nadezhda Kh Gorst, Oleg I Vinogradov, Tatyana K Ogarkova, Kamila V Shamtieva, Pavel V Alexandrov, Astanda V Mushba, Daria S Kanshina, Daria V Yakovleva, Maria A Surma, Ilia S Nikolaev, Nadezhda Kh Gorst

Abstract

Introduction: The majority of patients with severe COVID-19 suffer from delirium as the main sign of encephalopathy associated with this viral infection. The aim of this study was to identify early markers of the development of this condition.

Materials: The prospective cohort-based study included patients with community-acquired pneumonia and confirmed pulmonary tissue infiltration based on CT data, with a lesion consisting of at least 25% of one lung. The main group included patients who have developed acute encephalopathy (10 patients, 3 (30%) women; average age, 47.9 ± 7.3 years). The control group included patients who at discharge did not have acute encephalopathy (20 patients, 11 (55%) women; average age, 51.0 ± 10.5 years). The study collected clinical examination data, comprehensive laboratory data, neurophysiological data, pulse oximetry and CT data to identify the predictors of acute encephalopathy (study ClinicalTrials.gov identifier NCT04405544).

Results: Data analysis showed a significant relationship between encephalopathy with the degree of lung tissue damage, arterial hypertension, and type 2 diabetes mellitus, as well as with D-dimer, LDH, and lymphopenia.

Conclusions: The development of encephalopathy is secondary to the severity of the patient's condition since a more severe course of the coronavirus infection leads to hypoxic brain damage.

Keywords: COVID-19; SARS-CoV-2; delirium; encephalopathy.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
ROC curves for lymphocytes, D-dimer, PT, and LDH in prediction of encephalopathy in patients with COVID-19.

References

    1. Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., Kneen R., Defres S., Sejvar J., Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–783. doi: 10.1016/S1474-4422(20)30221-0.
    1. Mao L., Jin H., Wang M., Hu Y., Chen S., He Q. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–690. doi: 10.1001/jamaneurol.2020.1127.
    1. Beach S.R., Praschan N.C., Hogan C., Dotson S., Merideth F., Kontos N., Fricchione G.L., Smith F.A. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. Gen. Hosp. Psychiatry. 2020;65:47–53. doi: 10.1016/j.genhosppsych.2020.05.008.
    1. Khan B.A., Perkins A.J., Prasad N.K., Shekhar A., Campbell N.L., Gao S., Wang S., Khan S.H., Marcantonio E.R., Twigg H.L., et al. Biomarkers of Delirium Duration and Delirium Severity in the ICU. Crit. Care Med. 2020;48:353–361. doi: 10.1097/CCM.0000000000004139.
    1. Estabrooks C.A., Straus S.E., Flood C.M., Keefe J., Armstrong P., Donner G.J., Boscart V., Ducharme F., Silvius J.L., Wolfson M.C. Restoring trust: COVID-19 and the future of long-term care in Canada. Facets. 2020;5:651–691. doi: 10.1139/facets-2020-0056.
    1. Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O., Boulay C., Fafi-Kremer S., Ohana M., et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020;382:2268–2270. doi: 10.1056/NEJMc2008597.
    1. Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.
    1. Martinotti G., Barlati S., Prestia D., Palumbo C., Giordani M., Cuomo A., Miuli A., Paladini C., Amore M., Bondi E., et al. Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 mL immediate release. Psychopharmacology. 2020;237:3497–3501. doi: 10.1007/s00213-020-05644-3.
    1. Mat L.N.I., Sulaiman W.A.W., Kee H.F., Baharin M.A.S., Ghenesan S., Ishak S.N., Abidin W.F.Z., Daud N.L.F., Yun T.H. Clinical manifestations of delirium in elderly. MNJ (Malang Neurol. J.) 2018;4:78–85. doi: 10.21776/ub.mnj.2018.004.02.6.
    1. Mizuguchi M. Influenza encephalopathy and related neuropsychiatric syndromes. Influ. Other Respir. Viruses. 2013;7:67–71. doi: 10.1111/irv.12177.
    1. Kotfis K., Roberson S.W., Wilson J., Pun B., Ely E.W., Jeżowska I., Jezierska M., Dabrowski W. COVID-19: What do we need to know about ICU delirium during the SARS-CoV-2 pandemic? Anaesthesiol. Intensive Ther. 2020;52:132–138. doi: 10.5114/ait.2020.95164.
    1. Yadav H., Kor D.J. Platelets in the pathogenesis of acute respiratory distress syndrome. Am. J. Physiol. Cell. Mol. Physiol. 2015;309:L915–L923. doi: 10.1152/ajplung.00266.2015.
    1. Prokop M., van Everdingen W., van Rees Vellinga T., van Ufford J.Q., Stöger L., Beenen L., Geurts B., Gietema H., Krdzalic J., Schaefer-Prokop C., et al. CO-RADS–A categorical CT assessment scheme for patients with suspected COVID-19: Definition and evaluation. Radiology. 2020;296:E97–E104. doi: 10.1148/radiol.2020201473.
    1. Slooter A.J., Otte W.M., Devlin J.W., Arora R.C., Bleck T.P., Claassen J., Duprey M.S., Ely E.W., Kaplan P.W., Latronico N., et al. Updated nomencla-ture of delirium and acute encephalopathy: Statement of ten Societies. Intensive Care Med. 2020;46:1020–1022. doi: 10.1007/s00134-019-05907-4.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (DSM-5®) American Psychiatric Association; Arlington, VA, USA: 2013.
    1. World Health Organization . Criteria for Releasing COVID-19 Patients from Isolation: Scientific Brief, 17 June 2020 (No. WHO/2019-nCoV/Sci_Brief/Discharge_From_Isolation/2020.1) World Health Organization; Geneva, Switzerland: 2020.
    1. Hani C., Trieu N., Saab I., Dangeard S., Bennani S., Chassagnon G., Revel M.-P. COVID-19 pneumonia: A review of typical CT findings and differential diagnosis. Diagn. Interv. Imaging. 2020;101:263–268. doi: 10.1016/j.diii.2020.03.014.
    1. Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.
    1. Yum S.K., Moon C.-J., Youn Y.-A., Sung I.K. Changes in lactate dehydrogenase are associated with central gray matter lesions in newborns with hypoxic-ischemic encephalopathy. J. Matern. Neonatal Med. 2017;30:1177–1181. doi: 10.1080/14767058.2016.1208745.
    1. Sweetman D., Kelly L.A., Zareen Z., Nolan B., Murphy J., Boylan G., Donoghue V., Molloy E.J. Coagulation Profiles Are Associated With Early Clinical Outcomes in Neonatal Encephalopathy. Front. Pediatr. 2019;7:399. doi: 10.3389/fped.2019.00399.
    1. Lu Y., Li X., Geng D., Mei N., Wu P.-Y., Huang C.-C., Jia T., Zhao Y., Wang D., Xiao A., et al. Cerebral Micro-Structural Changes in COVID-19 Patients—An MRI-based 3-month Follow-up Study. EClinicalMedicine. 2020;25:100484. doi: 10.1016/j.eclinm.2020.100484.
    1. Vargas M., Servillo G. Serum lactate dehydrogenase as an early marker of posterior reversible encephalopathy syndrome: Keep your eyes open on the score of severity brain oedema. Anaesth. Intensive Care. 2013;41:436–437.
    1. Lv C., Gao B. Serum lactate dehydrogenase as a predictor of outcome in posterior reversible encephalopathy syndrome: Imperative to unify. Am. J. Neuroradiol. 2015;36:E29–E30. doi: 10.3174/ajnr.A4243.
    1. Scullen T., Keen J., Mathkour M., Dumont A.S., Kahn L. COVID-19 associated encephalopathies and cerebrovascular disease: The New Orleans experience. World Neurosurg. 2020;141:e437–e446. doi: 10.1016/j.wneu.2020.05.192.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe